TABLE 1.
Summary of signaling mechanisms of EETs in glucose metabolism evaluated in animal models of disease1
| Condition or disease | Experimental model | Treatment (reference) |
| Insulin resistance | Rats | CYP2J3 gene delivery (3, 22) |
| Type 2 diabetes | Mice | CYP2J3 gene delivery (3) |
| Obesity | Rats | CYP2J3 gene delivery (15) |
| Type 2 diabetes | Mice | CYP2J2 gene delivery (16) |
| Type 1 diabetes | Mice | CYP2J2 gene delivery (24, 25) |
| Insulin resistance | Mice | Knockout or inhibition of sEH (2, 19) |
| Type 1 diabetes | Mice | Knockout or inhibition of sEH (21) |
| NAFLD | Mice | Knockout of sEH (26) |
1
CYP, cytochrome P450; EET, epoxyeicosatrienoic acid; NAFLD, nonalcoholic fatty liver disease; sEH, soluble epoxide hydrolase.